Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.38 |
| ▸ | FAP | Q12884 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL138093 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL5017800 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL28231733 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL138092 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL1537461 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL1537458 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL1537322 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL1537321 | 1.00 | DPP4 (0.40) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL6535295 | 0.97 | DPP4 (0.39) | DPP4NOS2NOS3NOS1DPP8 | |
| Isoleucine SCHEMBL3692760 | 0.97 | DPP4 (0.39) | DPP4NOS2NOS3NOS1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511274-B | Casein hypoglycemic peptide and preparation method thereof | 华南理工大学 | 2022-01-11 | — | — | CN | disclosed |
| US-20120171158-A1 | METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS | INSTITUT PASTEUR (FR) | 2012-07-05 | — | — | US | disclosed |
| US-8124332-B2 | Methods of using sIP-10, CD26 inhibitors and CXCR3 levels in a sample to assess clearance of infection, response to interferon therapy, and treating chronic infections | INSTITUT PASTEUR (FR) | 2012-02-28 | — | — | US | disclosed |
| US-20100040577-A1 | METHODS OF USING sIP-10, CD26 INHIBITORS AND CXCR3 LEVELS IN A SAMPLE TO ASSESS CLEARANCE OF INFECTION, RESPONSE TO INTERFERON THERAPY, AND TREATING CHRONIC INFECTIONS | INSTITUT PASTEUR (FR) | 2010-02-18 | — | — | US | disclosed |
| EP-0756603-A1 | MULTIREPRESENTATION OF A PEPTIDE ANALOGUE OF THE DPPIV SUBSTRATE, ESPECIALLY OF THE KPR TYPE, TO INHIBIT THE ENTRY OF HIV IN CELLS | INSTITUT PASTEUR (FR) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995029190-A1 | MULTIREPRESENTATION OF A PEPTIDE ANALOGUE OF THE DPPIV SUBSTRATE, ESPECIALLY OF THE KPR TYPE, TO INHIBIT THE ENTRY OF HIV IN CELLS | INSTITUT PASTEUR (FR) | 1995-11-02 | — | — | WO | disclosed |
| WO-1994028915-A1 | HIV RETROVIRUS INFECTION INHIBITOR CAPABLE OF INTERACTING WITH CD26 RECEPTOR | INSTITUT PASTEUR (FR) | 1994-12-22 | — | — | WO | disclosed |